<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.475">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Type 2 diabetes in migrants: register-based analyses - 3&nbsp; Material and methods</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<link href="./4-results.html" rel="next">
<link href="./2-aims.html" rel="prev">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "sidebar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "start",
  "type": "textbox",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>

  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

</head>

<body class="nav-sidebar floating">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
  <nav class="quarto-secondary-nav" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
    <div class="container-fluid d-flex justify-content-between">
      <h1 class="quarto-secondary-nav-title"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Material and methods</span></h1>
      <button type="button" class="quarto-btn-toggle btn" aria-label="Show secondary navigation">
        <i class="bi bi-chevron-right"></i>
      </button>
    </div>
  </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article">
<!-- sidebar -->
  <nav id="quarto-sidebar" class="sidebar collapse sidebar-navigation floating overflow-auto">
    <div class="pt-lg-2 mt-2 text-left sidebar-header">
    <div class="sidebar-title mb-0 py-0">
      <a href="./">Type 2 diabetes in migrants: register-based analyses</a> 
    </div>
      </div>
      <div class="mt-2 flex-shrink-0 align-items-center">
        <div class="sidebar-search">
        <div id="quarto-search" class="" title="Search"></div>
        </div>
      </div>
    <div class="sidebar-menu-container"> 
    <ul class="list-unstyled mt-1">
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./index.html" class="sidebar-item-text sidebar-link">Cover Page</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-disclosure.html" class="sidebar-item-text sidebar-link">Financial disclosure</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-preface.html" class="sidebar-item-text sidebar-link">Preface</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-abbreviations.html" class="sidebar-item-text sidebar-link">Abbreviations</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./1-introduction.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./2-aims.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./3-methods.html" class="sidebar-item-text sidebar-link active"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Material and methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./4-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">4</span>&nbsp; <span class="chapter-title">Results in summary</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./5-discussion-methods.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">5</span>&nbsp; <span class="chapter-title">Discussion of methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./6-discussion-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">6</span>&nbsp; <span class="chapter-title">Discussion of results</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./7-conclusions.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">7</span>&nbsp; <span class="chapter-title">Conclusions and implications</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./8-perspectives.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">8</span>&nbsp; <span class="chapter-title">Perspectives and future research</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./references.html" class="sidebar-item-text sidebar-link">References</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-english.html" class="sidebar-item-text sidebar-link">English summary</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-danish.html" class="sidebar-item-text sidebar-link">Dansk resum√©</a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">Appendices</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-1" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./app1-papers.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">A</span>&nbsp; <span class="chapter-title">Appendix A</span></a>
  </div>
</li>
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./app2-supplementary.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">B</span>&nbsp; <span class="chapter-title">Appendix B</span></a>
  </div>
</li>
      </ul>
  </li>
    </ul>
    </div>
</nav>
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#setting-the-danish-healthcare-system" id="toc-setting-the-danish-healthcare-system" class="nav-link active" data-scroll-target="#setting-the-danish-healthcare-system"><span class="toc-section-number">3.1</span>  Setting: The Danish healthcare system</a></li>
  <li><a href="#register-data-sources" id="toc-register-data-sources" class="nav-link" data-scroll-target="#register-data-sources"><span class="toc-section-number">3.2</span>  Register data sources</a>
  <ul class="collapse">
  <li><a href="#the-danish-civil-registration-system" id="toc-the-danish-civil-registration-system" class="nav-link" data-scroll-target="#the-danish-civil-registration-system"><span class="toc-section-number">3.2.1</span>  The Danish Civil Registration System</a></li>
  <li><a href="#the-danish-national-patient-register" id="toc-the-danish-national-patient-register" class="nav-link" data-scroll-target="#the-danish-national-patient-register"><span class="toc-section-number">3.2.2</span>  The Danish National Patient Register</a></li>
  <li><a href="#the-danish-national-health-service-register" id="toc-the-danish-national-health-service-register" class="nav-link" data-scroll-target="#the-danish-national-health-service-register"><span class="toc-section-number">3.2.3</span>  The Danish National Health Service Register</a></li>
  <li><a href="#the-danish-national-prescription-registry" id="toc-the-danish-national-prescription-registry" class="nav-link" data-scroll-target="#the-danish-national-prescription-registry"><span class="toc-section-number">3.2.4</span>  The Danish National Prescription Registry</a></li>
  <li><a href="#the-danish-register-of-laboratory-results-for-research" id="toc-the-danish-register-of-laboratory-results-for-research" class="nav-link" data-scroll-target="#the-danish-register-of-laboratory-results-for-research"><span class="toc-section-number">3.2.5</span>  The Danish Register of Laboratory Results for Research</a></li>
  </ul></li>
  <li><a href="#diabetes-classification-algorithms" id="toc-diabetes-classification-algorithms" class="nav-link" data-scroll-target="#diabetes-classification-algorithms"><span class="toc-section-number">3.3</span>  Diabetes classification algorithms</a>
  <ul class="collapse">
  <li><a href="#the-open-source-diabetes-classifier" id="toc-the-open-source-diabetes-classifier" class="nav-link" data-scroll-target="#the-open-source-diabetes-classifier"><span class="toc-section-number">3.3.1</span>  The Open-Source Diabetes Classifier</a></li>
  <li><a href="#the-register-of-selected-chronic-diseases" id="toc-the-register-of-selected-chronic-diseases" class="nav-link" data-scroll-target="#the-register-of-selected-chronic-diseases"><span class="toc-section-number">3.3.2</span>  The Register of Selected Chronic Diseases</a></li>
  </ul></li>
  <li><a href="#questionnaire-data-used-in-validation" id="toc-questionnaire-data-used-in-validation" class="nav-link" data-scroll-target="#questionnaire-data-used-in-validation"><span class="toc-section-number">3.4</span>  Questionnaire data used in validation</a>
  <ul class="collapse">
  <li><a href="#the-health-in-central-denmark-survey" id="toc-the-health-in-central-denmark-survey" class="nav-link" data-scroll-target="#the-health-in-central-denmark-survey"><span class="toc-section-number">3.4.1</span>  The Health In Central Denmark survey</a></li>
  <li><a href="#the-national-health-survey" id="toc-the-national-health-survey" class="nav-link" data-scroll-target="#the-national-health-survey"><span class="toc-section-number">3.4.2</span>  The National Health Survey</a></li>
  </ul></li>
  <li><a href="#study-design-and-population" id="toc-study-design-and-population" class="nav-link" data-scroll-target="#study-design-and-population"><span class="toc-section-number">3.5</span>  Study design and population</a>
  <ul class="collapse">
  <li><a href="#study-populations" id="toc-study-populations" class="nav-link" data-scroll-target="#study-populations"><span class="toc-section-number">3.5.1</span>  Study populations</a></li>
  <li><a href="#outcomes" id="toc-outcomes" class="nav-link" data-scroll-target="#outcomes"><span class="toc-section-number">3.5.2</span>  Outcomes</a></li>
  <li><a href="#primary-variable-of-interest-migrant-status" id="toc-primary-variable-of-interest-migrant-status" class="nav-link" data-scroll-target="#primary-variable-of-interest-migrant-status"><span class="toc-section-number">3.5.3</span>  Primary variable of interest: migrant status</a></li>
  <li><a href="#other-explanatory-variables" id="toc-other-explanatory-variables" class="nav-link" data-scroll-target="#other-explanatory-variables"><span class="toc-section-number">3.5.4</span>  Other explanatory variables</a></li>
  </ul></li>
  <li><a href="#statistical-analysis" id="toc-statistical-analysis" class="nav-link" data-scroll-target="#statistical-analysis"><span class="toc-section-number">3.6</span>  Statistical analysis</a></li>
  <li><a href="#ethics-and-approvals" id="toc-ethics-and-approvals" class="nav-link" data-scroll-target="#ethics-and-approvals"><span class="toc-section-number">3.7</span>  Ethics and approvals</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title"><span id="sec-methods" class="quarto-section-identifier d-none d-lg-block"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Material and methods</span></span></h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<p>This chapter describes the healthcare setting and the register data sources underlying the studies of this PhD project. Secondly, the diabetes classification algorithms used in the project are described, as well as the sources of survey data used to validate them. The last half of the chapter goes over the study designs, populations and statistical methods of the three papers associated with the dissertation.</p>
<section id="setting-the-danish-healthcare-system" class="level2" data-number="3.1">
<h2 data-number="3.1" class="anchored" data-anchor-id="setting-the-danish-healthcare-system"><span class="header-section-number">3.1</span> Setting: The Danish healthcare system</h2>
<p>Denmark is divided into 5 administrative regions that are responsible for providing public healthcare services to their residents through public hospitals and contract agreements with private actors in the primary care sector. Private actors include GPs and other specialist practices (e.g.&nbsp;ophthalmologists), as well as other healthcare professionals (e.g.&nbsp;podiatrists). In addition, the 98 Danish municipalities are obliged to offer resources to prevent and/or manage chronic disease, such as programs on managing T2D through diet and physical exercise.</p>
<p>Although referral to outpatient hospital care is possible, patients with T2D are primarily treated at the GP, which native Danes and migrants with residence permit have free access to. In the tax-funded Danish public healthcare system, Danish citizens and migrants with residence permit have equal access to services, and nearly all services are provided free of charge, although T2D patients incur some out-of-pocket co-payments for podiatrist care and prescription drug purchases at pharmacies. Yearly co-payments towards medication expenditures are partially covered from ‚Ç¨132 and expenditures beyond ‚Ç¨553 are fully covered (2019 limits),<span class="citation" data-cites="reimbursement"><sup><a href="references.html#ref-reimbursement" role="doc-biblioref">1</a></sup></span> while 50% of all expenditures towards diabetes-specific podiatrist care are covered by the the public health insurance.<span class="citation" data-cites="okportal"><sup><a href="references.html#ref-okportal" role="doc-biblioref">2</a></sup></span></p>
</section>
<section id="register-data-sources" class="level2" data-number="3.2">
<h2 data-number="3.2" class="anchored" data-anchor-id="register-data-sources"><span class="header-section-number">3.2</span> Register data sources</h2>
<p>In Denmark, civil registration, public healthcare contacts, and drug prescriptions are recorded with a unique personal identifier (the <em>CPR number</em>) given to all Danish residents at immigration or birth. This enables coverage of the entire population and complete linkage between data sources, and forms the foundation of several nationwide Danish healthcare registers.<span class="citation" data-cites="regsoverview"><sup><a href="references.html#ref-regsoverview" role="doc-biblioref">3</a></sup></span> The following section briefly describes the data extracted from these registers, as well as other data sources used in the PhD project. A detailed list of variables and code values used is available in <a href="app2-supplementary.html">Supplementary material&nbsp;<span>B</span></a>.</p>
<section id="the-danish-civil-registration-system" class="level3" data-number="3.2.1">
<h3 data-number="3.2.1" class="anchored" data-anchor-id="the-danish-civil-registration-system"><span class="header-section-number">3.2.1</span> The Danish Civil Registration System</h3>
<p>The Danish Civil Registration System contains civil registration data on all residents in Denmark. Information on migrations and country of origin was extracted, in addition to data on age, sex, equivalised disposable household income,<span class="citation" data-cites="eurostat_equiv"><sup><a href="references.html#ref-eurostat_equiv" role="doc-biblioref">4</a></sup></span> employment status, and region of residence.</p>
</section>
<section id="the-danish-national-patient-register" class="level3" data-number="3.2.2">
<h3 data-number="3.2.2" class="anchored" data-anchor-id="the-danish-national-patient-register"><span class="header-section-number">3.2.2</span> The Danish National Patient Register</h3>
<p>The Danish National Patient Register contains information on all hospital admissions and outpatient contacts. Data on diagnoses of diabetes and cardiovascular complications, and procedures relating to retinal screening and treatment of cardiovascular complications was extracted from 1994 through 2018. At the time of this PhD project, the clinical coding system in use was the International Classification of Diseases, <span class="math inline">\(10th\)</span> revision (<em>ICD-10</em>), implemented in 1994.<span class="citation" data-cites="icd10"><sup><a href="references.html#ref-icd10" role="doc-biblioref">5</a></sup></span></p>
</section>
<section id="the-danish-national-health-service-register" class="level3" data-number="3.2.3">
<h3 data-number="3.2.3" class="anchored" data-anchor-id="the-danish-national-health-service-register"><span class="header-section-number">3.2.3</span> The Danish National Health Service Register</h3>
<p>The Danish National Health Service Register contains information on all public healthcare services provided in the primary care sector. The data is essentially billing information, and serves as the basis for payment to the healthcare provider from the Danish regions. Each type of service has a unique <em>SPECIALE</em>-code (e.g.&nbsp;all diabetes-specific podiatrist care services are contained as sub-codes under <em>SPECIALE</em>-code 54) Information on diabetes-specific services performed at podiatrist and ophthalmologist practices from 1990 through 2018 was extracted, as well as point-of-care HbA1c testing performed at GPs.</p>
</section>
<section id="the-danish-national-prescription-registry" class="level3" data-number="3.2.4">
<h3 data-number="3.2.4" class="anchored" data-anchor-id="the-danish-national-prescription-registry"><span class="header-section-number">3.2.4</span> The Danish National Prescription Registry</h3>
<p>The Danish National Prescription Registry contains information on all prescription drug purchases at Danish pharmacies, classified according to the Anatomical Therapeutic Chemical (ATC) Classification. These registrations serve to determine reimbursement awarded to each purchase from the public health insurance. Information on purchases of GLD, LLD, ACEI, ARB, and APT from 1995 through 2018 was extracted.</p>
</section>
<section id="the-danish-register-of-laboratory-results-for-research" class="level3" data-number="3.2.5">
<h3 data-number="3.2.5" class="anchored" data-anchor-id="the-danish-register-of-laboratory-results-for-research"><span class="header-section-number">3.2.5</span> The Danish Register of Laboratory Results for Research</h3>
<p>The Danish Register of Laboratory Results for Research contains information on clinical biomarker samples analysed at clinical biochemistry departments in hospitals around Denmark. With the exception of point-of-care tests, all biomarker samples taken in the primary healthcare sector are sent for analysis in hospital laboratories. Compared to the other registers, this is a relatively new data source, initially launched in 2013, and only recently achieved nationwide coverage.<span class="citation" data-cites="rlrr"><sup><a href="references.html#ref-rlrr" role="doc-biblioref">6</a></sup></span></p>
<p>At the time of data extraction, the Central Denmark Region, one of five administrative regions in Denmark (population of 1.3 million inhabitants, 22% of the entire Danish population) was not yet covered in the register. To address this issue, laboratory results from this part of the the population were extracted directly from the <em>Clinical Laboratory Information System</em>, a clinical database that stores all laboratory results analysed in Central Denmark Region. Data on HbA1c, LDL-C, and UACR analyses were extracted from 2011 through 2018.</p>
</section>
</section>
<section id="diabetes-classification-algorithms" class="level2" data-number="3.3">
<h2 data-number="3.3" class="anchored" data-anchor-id="diabetes-classification-algorithms"><span class="header-section-number">3.3</span> Diabetes classification algorithms</h2>
<p>As described previously in <a href="1-introduction.html#sec-register-based-diabetes-classifiers"><span>Section&nbsp;1.5.4</span></a>, currently available register-based diabetes classifiers have yet to incorporate the emerging register data on routine HbA1c testing, despite recommendations to do so. Wishing to take advantage of this data, we developed a new classifier, the OSDC. As a point of reference, we developed an implementation of the RSCD diabetes classifier (version 1.0, August 2016) according to official documentation.<span class="citation" data-cites="ruks1doc"><sup><a href="references.html#ref-ruks1doc" role="doc-biblioref">7</a></sup></span></p>
<p>The following sections describe the algorithms behind these diabetes classifiers. Pros and cons of their design are discussed in <a href="5-discussion-methods.html">Chapter&nbsp;<span>5</span></a>.</p>
<section id="the-open-source-diabetes-classifier" class="level3" data-number="3.3.1">
<h3 data-number="3.3.1" class="anchored" data-anchor-id="the-open-source-diabetes-classifier"><span class="header-section-number">3.3.1</span> The Open-Source Diabetes Classifier</h3>
<p>This classifier first identifies a population of individuals with any type of diabetes mellitus, and then splits this population into T1D and T2D by identifying individuals with T1D and classifying the remainder of the diabetes population as T2D.</p>
<p>In OSDC, diabetes is defined at the second occurrence of any event across the four types of inclusion events listed below. All available data is used, except purchases of GLD, which are restricted to data from 1997 onwards.</p>
<ol type="i">
<li>HbA1c measurements of ‚â•48 mmol/mol, after censoring:
<ul>
<li>Results of samples taken during pregnancies - potential gestational diabetes mellitus (GDM).</li>
</ul></li>
<li>Hospital diagnoses of diabetes.</li>
<li>Diabetes-specific services received at podiatrist.</li>
<li>Purchases of GLD after censoring:
<ol type="1">
<li><p>Brand drugs for weight loss, e.g.&nbsp;<em>Saxenda.</em></p></li>
<li><p>Purchases during pregnancies - potential treatment of GDM.</p></li>
<li><p>Metformin purchases in women below age 40 - potential treatment of polycystic ovary syndrome (PCOS).</p></li>
</ol></li>
</ol>
<p>Diabetes type is classified as either T1D or T2D based on patterns of purchases of insulins (including analogues) and hospital primary diagnoses of T1D and T2D. Classification as T1D requires an individual to fulfill either of the following criteria:</p>
<ol type="a">
<li><p>Must have purchased only insulins and never any other type of GLD, and have at least one diagnosis of T1D</p></li>
<li><p>Must have a majority of T1D diagnoses from endocrinological departments (or from other medical departments, in the absence of contacts to endocrinological departments), and a purchase of insulin within 180 days after onset of diabetes, with insulin contributing at least two thirds of all defined daily doses of GLD purchased.<span class="citation" data-cites="ddd"><sup><a href="references.html#ref-ddd" role="doc-biblioref">8</a></sup></span></p></li>
</ol>
<p>In populations generated on a fixed index date (such as the cross-sectional studies associated with this dissertation), individuals classified as T1D must have purchased insulins in the last year prior to the index date.</p>
<p>Individuals not classified as T1D are classified as T2D.</p>
</section>
<section id="the-register-of-selected-chronic-diseases" class="level3" data-number="3.3.2">
<h3 data-number="3.3.2" class="anchored" data-anchor-id="the-register-of-selected-chronic-diseases"><span class="header-section-number">3.3.2</span> The Register of Selected Chronic Diseases</h3>
<p>Formally, the RSCD includes two separate algorithms, RSCD-T1D and RSCD-T2D, that identify T1D and T2D, respectively. In practice, however, they are inter-dependent, as individuals identified by the T2D classifier are excluded from the T1D classifier.</p>
<p>In RSCD, diabetes is defined by type-specific diagnoses of T1D or T2D, and purchases of GLD. Individuals are defined as having T1D or T2D if they meet any of the algorithm‚Äôs inclusion criteria without fulfilling any of its exclusion criteria.</p>
<section id="classification-of-type-2-diabetes" class="level4" data-number="3.3.2.1">
<h4 data-number="3.3.2.1" class="anchored" data-anchor-id="classification-of-type-2-diabetes"><span class="header-section-number">3.3.2.1</span> Classification of type 2 diabetes</h4>
<p>For classification of T2D, inclusion criteria include:</p>
<ol type="i">
<li>Any purchases of non-insulin GLD.</li>
<li>A hospital diagnosis of T2D as the most recent type-specific diabetes diagnosis.</li>
</ol>
<p>Exclusions from the T2D population include:</p>
<ol type="a">
<li>Women that have only purchased metformin and have any diagnoses of PCOS, purchases of clomifene or combination drugs containing antiandrogens and estrogens.</li>
<li>Individuals with only one recorded inclusion event.</li>
<li>Individuals with no recorded inclusion events in the last 10 years prior to the index date.</li>
</ol>
</section>
<section id="classification-of-type-1-diabetes" class="level4" data-number="3.3.2.2">
<h4 data-number="3.3.2.2" class="anchored" data-anchor-id="classification-of-type-1-diabetes"><span class="header-section-number">3.3.2.2</span> Classification of type 1 diabetes</h4>
<p>For classification of T1D, inclusion criteria include:</p>
<ol type="i">
<li>Any purchases of insulins.</li>
<li>A hospital diagnosis of T1D as the most recent type-specific diabetes diagnosis.</li>
</ol>
<p>Exclusions from the T1D population include:</p>
<ol type="a">
<li>Women with any diagnoses of GDM, who have made purchases of GLD only in the period between 280 days prior to their first diagnosis of GDM and 280 days after their last diagnosis of GDM.</li>
<li>Individuals classified as T2D.</li>
<li>Individuals without any purchases of GLD, or have made only one purchase and have no hospital records of T1D.</li>
<li>Individuals with no insulin purchases in the last 10 years prior to the index date.</li>
</ol>
</section>
</section>
</section>
<section id="questionnaire-data-used-in-validation" class="level2" data-number="3.4">
<h2 data-number="3.4" class="anchored" data-anchor-id="questionnaire-data-used-in-validation"><span class="header-section-number">3.4</span> Questionnaire data used in validation</h2>
<p>To validate the above diabetes classifiers, self-reported data from two surveys was retrieved. The design and contents of these surveys is described below.</p>
<section id="the-health-in-central-denmark-survey" class="level3" data-number="3.4.1">
<h3 data-number="3.4.1" class="anchored" data-anchor-id="the-health-in-central-denmark-survey"><span class="header-section-number">3.4.1</span> The Health In Central Denmark survey</h3>
<p>Health in Central Denmark is a digital and postal questionnaire survey conducted in the Central Denmark Region. The survey was conducted in 2020 on all inhabitants aged 18 to 74 years identified as prevalent diabetes cases by OSDC on 31 Dec 2018, plus an equally-sized group of OSDC non-diabetes cases (matched to diabetes cases by sex, age, and municipality). The survey collected self-reported data related to health in general, with an additional focus on items related to diabetes mellitus, such as current disease, diabetes type, and age at onset.In total, 44,659 OSDC diabetes cases and 46,195 matched OSDC non-diabetes cases were invited to the survey, and 51,854 (57%) responded.<span class="citation" data-cites="hicd"><sup><a href="references.html#ref-hicd" role="doc-biblioref">9</a></sup></span></p>
</section>
<section id="the-national-health-survey" class="level3" data-number="3.4.2">
<h3 data-number="3.4.2" class="anchored" data-anchor-id="the-national-health-survey"><span class="header-section-number">3.4.2</span> The National Health Survey</h3>
<p>The National Health Survey is a repeated digital and postal questionnaire survey conducted among a representative sample of Danish residents aged 16 or above. It collects self-reported data related to mental and physical health in general, such as current or former chronic diseases, and includes a question on diabetes of any type.<span class="citation" data-cites="nhs"><sup><a href="references.html#ref-nhs" role="doc-biblioref">10</a></sup></span> In the 2017 survey of Central Denmark Region, 52,000 individuals were invited and 32,400 (62%) responded. Data from this survey was used in supplementary validation analyses.</p>
</section>
</section>
<section id="study-design-and-population" class="level2" data-number="3.5">
<h2 data-number="3.5" class="anchored" data-anchor-id="study-design-and-population"><span class="header-section-number">3.5</span> Study design and population</h2>
<p>In addition to developing a code package for the statistical programming language <em>R</em> containing the source-code behind the diabetes classifiers, three studies were conducted. Study I was designed to examine the validity of register-based definitions of T1D and T2D. After validating the two candidate classifiers, the most accurate classifier - OSDC - was chosen to identify study populations of T2D for use in studies II and III.</p>
<p><em>[Overview table of the three studies]</em></p>
<section id="study-populations" class="level3" data-number="3.5.1">
<h3 data-number="3.5.1" class="anchored" data-anchor-id="study-populations"><span class="header-section-number">3.5.1</span> Study populations</h3>
<section id="study-i" class="level4" data-number="3.5.1.1">
<h4 data-number="3.5.1.1" class="anchored" data-anchor-id="study-i"><span class="header-section-number">3.5.1.1</span> Study I</h4>
<p>Validation analyses were performed in a subset of respondents in the Health in Central Denmark survey.</p>
<p>Among survey respondents, 2,411 were excluded due to missing data on diabetes items. 2,093 individuals with self-reported onset of diabetes after 31 December 2018 were excluded, as diabetes cases onset after the index date would erroneously evaluate to false-negative cases in the register-based classifiers, due to the delay from register-classification on the index date (31 December 2018) until questionnaire responses (November 2020).</p>
<p>After these exclusions, 47,350 individuals remained, but due to survey invites being conditioned on OSDC diabetes status, the survey population was biased towards the OSDC classification and OSDC diabetes prevalence was 43.7% (20,692 individuals). To account for this, we first estimated the OSDC diabetes prevalence to be 9.3% (2,483 individuals) in a random sample of 26,665 individuals from the background population with the same age, sex and municipality distributions as the OSDC non-diabetes cases of respondents. To offset the oversampling of OSDC diabetes cases in the survey, OSDC diabetes cases were randomly subsampled to 2,733 individuals to achieve an unbiased OSDC diabetes prevalence of 9.3% in the final study population of 29,391 individuals.</p>
</section>
<section id="study-ii" class="level4" data-number="3.5.1.2">
<h4 data-number="3.5.1.2" class="anchored" data-anchor-id="study-ii"><span class="header-section-number">3.5.1.2</span> Study II</h4>
<p>Register data was used to identify 262,837 individuals with prevalent T2D on 1 January 2018 (index date) from a background population of 3,864,528 native Danes or first-generation migrants from the selected origin categories aged 25 - 99 years, and residing at least 3 years in Denmark on the index date.</p>
<p>T2D prevalence was studied in the above population. In order to study T2D care where it was clinically relevant, the analyses of T2D care were performed in a distinct subsets of the population with T2D, as outlined below:</p>
<ul>
<li>All analyses of T2D care were performed in a subset of 254,097 individuals with T2D onset at least 6 months prior to the index date in order to allow time for baseline-screening, initiation of pharmacological treatment and subsequent biomarker control to occur in the newly-diagnosed.
<ul>
<li>Monitoring was evaluated among all these individuals:
<ul>
<li>Monitoring of HbA1c, LDL-C, nephropathy, retinopathy and foot disease: 254,097 individuals.</li>
</ul></li>
<li>Biomarker levels were evaluated in those with at least one measurement prior to the index date:
<ul>
<li>HbA1c levels: 250,075 individuals.</li>
<li>LDL-C levels: 248,813 individuals.</li>
</ul></li>
<li>Each analysis of pharmacological treatment was limited to individuals with a clear guideline-recommendation for that particular treatment according to complication status or biomarker levels on the index date (excluding individuals not alive and resident in Denmark in the year following the index date and thus unable to purchase medication):
<ul>
<li>GLD. HbA1c ‚â•48 mmol/mol at the most recent measurement: 140,208 individuals.</li>
<li>LLD. Prevalent macrovascular complications or DKD, or age above 40 with LDL-C above 2.5 mmol/L: 128,707 individuals.</li>
<li>ACEI/ARB &amp; APT. Prevalent macrovascular complications or DKD: 77,414 individuals.</li>
</ul></li>
</ul></li>
</ul>
</section>
<section id="study-iii" class="level4" data-number="3.5.1.3">
<h4 data-number="3.5.1.3" class="anchored" data-anchor-id="study-iii"><span class="header-section-number">3.5.1.3</span> Study III</h4>
<p>Register data was used to identify 275,525 individuals with prevalent T2D on 1 January 2019 (index date) from a background population of 4,084,564 individuals above age 25. Among individuals with T2D, 269,011 native Danes or first-generation migrants from the selected origin categories residing at least 3 years in Denmark on the index date were included. After exclusion of 5,518 individuals without records of HbA1c or LDL-cholesterol, the study population contained 263,393 individuals. A subsequent analysis of GLD use in the year 2021 was performed on 241,140 individuals from the above study population still alive and residing in Denmark on 1 January 2021.</p>
</section>
</section>
<section id="outcomes" class="level3" data-number="3.5.2">
<h3 data-number="3.5.2" class="anchored" data-anchor-id="outcomes"><span class="header-section-number">3.5.2</span> Outcomes</h3>
<section id="study-i-1" class="level4" data-number="3.5.2.1">
<h4 data-number="3.5.2.1" class="anchored" data-anchor-id="study-i-1"><span class="header-section-number">3.5.2.1</span> Study I</h4>
<p>The validation golden standard, self-reported diabetes type, was categorized as either T1D (self-reported T1D), T2D (all other types of diabetes) or no diabetes, corresponding to the diabetes types discernable by the register-based classifiers.</p>
</section>
<section id="study-ii-1" class="level4" data-number="3.5.2.2">
<h4 data-number="3.5.2.2" class="anchored" data-anchor-id="study-ii-1"><span class="header-section-number">3.5.2.2</span> Study II</h4>
<p>Twelve outcomes were defined as follows</p>
<ul>
<li>Prevalent T2D was defined as OSDC-classified T2D prevalent on the index date.</li>
</ul>
<p>T2D care quality was evaluated in the scope of failure to meet guideline recommendations in terms of monitoring (allowing for three months of leeway), biomarker levels, and pharmacological treatment.</p>
<p>T2D monitoring was evaluated in time-frames prior to index date, according to guideline-recommendations:</p>
<ul>
<li>Monitoring of HbA1c and LDL-C, as well as UACR-screening for diabetic nephropathy were identified by records of biomarker samples between October 1, 2016 and December 31, 2017 in the <em>Register of Laboratory Results for Research</em> or the <em>Clinical Laboratory Information System</em>. Additional monitoring of HbA1c using point-of-care tests was identified by records in the <em>National Health Service Register</em>.</li>
<li>Screening for diabetic retinopathy was identified by records of retinal photoscreening for diabetic retinopathy between October 1, 2015 and December 31, 2017 - either at hospital departments in the <em>National Patient Register</em>, or diabetes-specific examinations at ophthalmologist practice recorded in the <em>National Health Service Register .</em></li>
<li>Screening for diabetic foot disease was identified by records of diabetes-specific podiatrist services received between October 1, 2016 and December 31, 2017 in the <em>National Health Service Register.</em></li>
</ul>
<p>Biomarker levels on the index date was evaluated using the most recent measurement of HbA1c and LDL-C before the index date:</p>
<ul>
<li>The outcome measure for HbA1c control was a level ‚â•53 mmol/mol.</li>
<li>For LDL-C, the outcome measure was a level ‚â•2.6 mmol/L.</li>
</ul>
<p>Pharmacological treatment was assessed in the year following the index date, and treatment was defined by at least one purchase of the respective type of drug based on the following ATC codes (including subcodes):</p>
<ul>
<li>GLD: ATC A10.</li>
<li>LLD: ATC C10.</li>
<li>ACEI/ARB: ATC C09A-C09D.</li>
<li>APT: ATC B01AC.</li>
</ul>
</section>
<section id="study-iii-1" class="level4" data-number="3.5.2.3">
<h4 data-number="3.5.2.3" class="anchored" data-anchor-id="study-iii-1"><span class="header-section-number">3.5.2.3</span> Study III</h4>
<p>Use of individual GLD types was defined by any purchases made during the respective year (2019 and 2021). Purchase of the following types of GLD counted towards the total number of drugs used by an individual in a year (fixed-dose combination drugs counting towards both of their component drug types):</p>
<ol type="1">
<li>Metformin: A10BA02, A10BD0, A10BD10-16, A10BD20, A10BD23.</li>
<li>Sulfonylureas: A10BB.</li>
<li>DPP4i: A10BH, A10BD0, A10BD10-11, A10BD13, A10BD19, A10BD21, A10BD24.</li>
<li>SGLT2i: A10BK, A10BD15-24, A10BX09, A10BX11-12.</li>
<li>Insulins (including analogues): A10A.</li>
<li>GLP1RA: A10BJ, A10AE5, A10BX04, A10BX07, A10BX10, A10BX13-14.</li>
<li>Thiazolidinediones: A10BG.</li>
<li>Repaglinide: A10BX02.</li>
</ol>
<p>Separate outcomes for the use of each individual GLD type were defined for metformin, sulfonylurea, DPP4i, SGLT2i, insulins, and GLP1RA. In addition, combination therapy was analysed using the following two outcome definitions:</p>
<ul>
<li><p>Any combination therapy: two or more drug types purchased in the year</p></li>
<li><p>Triple combination therapy: three or more drug types purchased in the year.</p></li>
</ul>
</section>
</section>
<section id="primary-variable-of-interest-migrant-status" class="level3" data-number="3.5.3">
<h3 data-number="3.5.3" class="anchored" data-anchor-id="primary-variable-of-interest-migrant-status"><span class="header-section-number">3.5.3</span> Primary variable of interest: migrant status</h3>
<p>Migrant status and country of origin was defined according to the definitions by Statistics Denmark. Based on the national origins with the most T2D cases and the United Nations M49 geoscheme, the population was grouped into nine origin categories:</p>
<ul>
<li>Native Danes</li>
<li>Europe (M49: Europe, except countries of the former Yugoslavia)</li>
<li>Middle East (M49: Northern Africa, Western Asia except Turkey, plus Afghanistan and Iran)</li>
</ul>
<p>And the six remaining individual countries with the most T2D cases (in order of number of cases):</p>
<ul>
<li>Turkey</li>
<li>Former Yugoslavia</li>
<li>Pakistan</li>
<li>Sri Lanka</li>
<li>Somalia</li>
<li>Vietnam</li>
</ul>
</section>
<section id="other-explanatory-variables" class="level3" data-number="3.5.4">
<h3 data-number="3.5.4" class="anchored" data-anchor-id="other-explanatory-variables"><span class="header-section-number">3.5.4</span> Other explanatory variables</h3>
<section id="socioeconomic-variables" class="level4" data-number="3.5.4.1">
<h4 data-number="3.5.4.1" class="anchored" data-anchor-id="socioeconomic-variables"><span class="header-section-number">3.5.4.1</span> Socioeconomic variables</h4>
<p>Age and diabetes-duration on index dates were treated as continuous variables. Household income was based on the 3-year average of equivalised disposable household income prior to index dates, converted to the corresponding percentile in the background population and treated as a continuous variable. As a measure of acculturation, duration of residence was calculated from the date of first migration into Denmark, converted to a categorical variable with native Danes categorized in the maximally acculturated group. Employment status was categorized as <em>Employed</em> (including students and others), <em>Retired</em> or <em>Unemployed</em> based on the year prior to index dates.</p>
</section>
<section id="clinical-variables" class="level4" data-number="3.5.4.2">
<h4 data-number="3.5.4.2" class="anchored" data-anchor-id="clinical-variables"><span class="header-section-number">3.5.4.2</span> Clinical variables</h4>
<p>Prevalent macrovascular complications were assessed by primary diagnosis codes of stroke, ischemic heart disease and peripheral arterial disease (and associated procedure codes) prior to index dates. Diabetic kidney disease was defined as a UACR ‚â•300 mg/g measured within three years prior to index dates (study II: within 27 months). Other types of microvascular complications were not included due to insufficient data.</p>
<p>Study III used HbA1c levels and LDL-C levels at baseline as continuous covariates for adjustment, as well as LLD use within a year prior to the index date. Finally, analyses of the use of individual GLD drug types in study III adjusted for combination therapy categorized as <em>Monotherapy or no GLD</em>, <em>Dual combination</em> and <em>Triple combination or more</em>.</p>
</section>
</section>
</section>
<section id="statistical-analysis" class="level2" data-number="3.6">
<h2 data-number="3.6" class="anchored" data-anchor-id="statistical-analysis"><span class="header-section-number">3.6</span> Statistical analysis</h2>
<p>Statistical analyses were performed in RStudio<span class="citation" data-cites="RStudio"><sup><a href="references.html#ref-RStudio" role="doc-biblioref">11</a></sup></span> using R version 4<span class="citation" data-cites="R"><sup><a href="references.html#ref-R" role="doc-biblioref">12</a></sup></span> and a range of open-source code packages for computations<span class="citation" data-cites="datatable Epi finalfit tidyverse geepack"><sup><a href="references.html#ref-datatable" role="doc-biblioref">13</a>‚Äì<a href="references.html#ref-geepack" role="doc-biblioref">17</a></sup></span> and visualisation.<span class="citation" data-cites="diagrammer khroma"><sup><a href="references.html#ref-diagrammer" role="doc-biblioref">18</a>,<a href="references.html#ref-khroma" role="doc-biblioref">19</a></sup></span></p>
<p>This section describes our overall statistical analysis strategy, followed by the specific statistical analyses of each study.</p>
<p>Logistic regression - a statistical model that computes odds ratios (OR) between groups - is often applied in cross-sectional studies to estimate relative risk (RR, or risk ratio). However, odds ratios approximate relative risk <strong>only</strong> when the outcome is <em>rare</em>. If this is not the case, interpreting ORs as RRs will exaggerate risk estimates,<span class="citation" data-cites="Grant2014"><sup><a href="references.html#ref-Grant2014" role="doc-biblioref">20</a></sup></span> as illustrated in <a href="#fig-or-rr">Figure&nbsp;<span>3.1</span></a> (adapted from <a href="https://commons.wikimedia.org/w/index.php?curid=100175653">D Wells - CC-BY-SA</a>).</p>
<div class="cell">
<div class="cell-output-display">
<div id="fig-or-rr" class="quarto-figure quarto-figure-center anchored">
<figure class="figure">
<p><img src="3-methods_files/figure-html/fig-or-rr-1.png" class="img-fluid figure-img" width="672"></p>
<p></p><figcaption class="figure-caption">Figure&nbsp;3.1: Relationship between odds ratio and relative risk depending on baseline risk.</figcaption><p></p>
</figure>
</div>
</div>
</div>
<p>None of the outcomes in studies II &amp; III were expected to be rare, and thus logistic regression was unsuitable. While log-binomial regression models are the most natural choice for computing relative risk in a mathematical sense, they are prone to convergence failure.<span class="citation" data-cites="convergencefail"><sup><a href="references.html#ref-convergencefail" role="doc-biblioref">21</a></sup></span> Given the large number of outcomes and models that needed fitting, this presented a serious (although not insurmountable) inconvenience, and log-binomial regression was also discarded.</p>
<p>Robust Poisson regression (sometimes termed modified Poisson regression)<span class="citation" data-cites="Zou2004"><sup><a href="references.html#ref-Zou2004" role="doc-biblioref">22</a></sup></span> presented an appealing alternative for modeling RR. A comprehensive description of the technique is beyond the scope of this dissertation, but a brief explanation is in order, since ordinary Poisson regression is not the right tool for modeling binary outcomes as such data violate the assumptions behind the model.<span class="citation" data-cites="regresscounts"><sup><a href="references.html#ref-regresscounts" role="doc-biblioref">23</a></sup></span> When applied to binomial data, the error for the estimated relative risk will be overestimated in an ordinary Poisson model. However, this problem can be addressed by using robust generalized estimating equations (so-called <em>sandwich</em>) variance estimates, which provide accurate standard errors in the presence of over-dispersion and excess zeros,<span class="citation" data-cites="Greenland2004"><sup><a href="references.html#ref-Greenland2004" role="doc-biblioref">24</a></sup></span> such as in a binary distribution. Ultimately, this allows robust Poisson regression to estimate RR with valid confidence intervals in data with binary outcomes.<span class="citation" data-cites="compareperformance"><sup><a href="references.html#ref-compareperformance" role="doc-biblioref">25</a></sup></span></p>
<p>All regression models were modeled with native Danes as the reference group. To account for potential non-linearity, continuous variables were modeled as natural splines with knots placed at each quintile of the distribution in the respective study population. Supplementary analyses where continuous variable were modeled as categorical variables (quintiles) were conducted for easier interpretation of these variables. Supplementary analyses also included estimates of absolute risk differences corresponding to the above analyses. In these analyses, a generalized linear model using a Gaussian distribution and identity link with robust <em>sandwich</em> variance estimates was used to compute absolute risk difference with 95% confidence intervals.</p>
<p>In all three studies, the characteristics of study populations were presented, describing continuous variables with means and standard differences, and categorical variables by absolute numbers and percentage proportions. In study I, characteristics were tabulated according to self-reported, OSDC-classified, and RSCD-classified diabetes type, while study II and III tabulated the distribution of covariates and outcomes by origin group.</p>
<p>The following sections describes the statistical analyses of each study.</p>
<section id="study-i-2" class="level4" data-number="3.6.0.1">
<h4 data-number="3.6.0.1" class="anchored" data-anchor-id="study-i-2"><span class="header-section-number">3.6.0.1</span> Study I</h4>
<p>Validation analyses were performed separately for T1D and T2D, where each register-based diabetes classifier was validated against self-reported diabetes type. Within analyses of each diabetes type, diabetes type was modeled as a distinct binary variable: does the individual have this diabetes type or not (e.g.&nbsp;in the analyses of T1D, diabetes type was modeled as a binary variable of T1D vs.&nbsp;no T1D, the latter category including both T2D and non-diabetes cases).</p>
<p>Concordance tables and associated validation metrics were computed (with 95% confidence intervals) as defined in equations <a href="#eq-sens"><span>3.1</span></a>, <a href="#eq-spec"><span>3.2</span></a>, <a href="#eq-ppv"><span>3.3</span></a>, and <a href="#eq-npv"><span>3.4</span></a>: sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). These validation analyses were bootstrapped in 1000 random subsamples in order to assess robustness.</p>
<p><span id="eq-sens"><span class="math display">\[ Sensitivity = \frac{N_{true positives}}{N_{true positives}+N_{false negatives}} \tag{3.1}\]</span></span></p>
<p><span id="eq-spec"><span class="math display">\[ Specificity = \frac{N_{true negatives}}{N_{true negatives}+N_{false positives}} \tag{3.2}\]</span></span></p>
<p><span id="eq-ppv"><span class="math display">\[ PPV = \frac{N_{true positives}}{N_{true positives}+N_{false positives}} \tag{3.3}\]</span></span></p>
<p><span id="eq-npv"><span class="math display">\[ NPV = \frac{N_{true negatives}}{N_{true negatives}+N_{false negatives}} \tag{3.4}\]</span></span></p>
<p>Furthermore, analyses stratified by self-reported age at onset of diabetes (including all self-reported non-diabetes cases in both strata of age at onset) were performed to assess the influence of age at onset of diabetes on sensitivity and PPV.</p>
</section>
<section id="study-ii-2" class="level4" data-number="3.6.0.2">
<h4 data-number="3.6.0.2" class="anchored" data-anchor-id="study-ii-2"><span class="header-section-number">3.6.0.2</span> Study II</h4>
<p>Robust Poisson regression was used to compute RR and 95% confidence intervals in a series of cross-sectional analyses of T2D prevalence and eleven outcomes within T2D care.</p>
<p>In the analysis of T2D prevalence, RR of prevalent T2D was computed in a crude model and in two models with different levels of adjustment to explore the effects of clinical (model 1) and socioeconomic factors (model 2) on migrant risks. The first model adjusted for sex and age (model 1); the second model further adjusted for employment status, household income, duration of residence, and region of residence (model 2). Additionally, age-specific T2D prevalence in each migrant group was modeled using a binomial model with log-link and restricted cubic splines as a function of age.</p>
<p>In the eleven analyses of T2D care, the RR of not receiving each type of guideline-level T2D care was computed in a crude model and in two adjusted models to visualize risk disparities in a clinical context separately from the fully-adjusted model. The first model (model 1) adjusted for clinical risk factors in diabetes that may influence decision-making when planning diabetes care with the patient (sex, age, diabetes duration, prevalent macrovascular complications and DKD). The fully-adjusted model (model 2) further adjusted for socioeconomic factors that may influence a patient‚Äôs health behavior and healthcare service usage (employment status, household income, duration of residence, and region of residence).</p>
<p>In order to assess potential disparities at other cut-off values of HbA1c and LDL-C, cumulative empirical distributions were plotted with 95% confidence intervals computed with Kolmogorov-Smirnov‚Äôs <em>D</em>.</p>
</section>
<section id="study-iii-2" class="level4" data-number="3.6.0.3">
<h4 data-number="3.6.0.3" class="anchored" data-anchor-id="study-iii-2"><span class="header-section-number">3.6.0.3</span> Study III</h4>
<p>Similar to study II, robust Poisson regression was used to compute RR with 95% confidence intervals in three models for each outcome: an unadjusted model (crude), a model adjusted for clinical risk factors (model 1), and a model adjusted for clinical and socioeconomic factors (model 2). Compared to the models in study II, all adjusted models in this study contained adjustment for additional clinical risk factors (HbA1c level, LDL-C level, and lipid-lowering drug usage), and the analyses of individual GLD type also including adjustment for the degree of combination therapy.</p>
</section>
</section>
<section id="ethics-and-approvals" class="level2" data-number="3.7">
<h2 data-number="3.7" class="anchored" data-anchor-id="ethics-and-approvals"><span class="header-section-number">3.7</span> Ethics and approvals</h2>
<p>In compliance with the General Data Protection Regulation, the handling of personal data associated with this PhD project was registered in the internal register of research projects (Danish: <em>fortegnelsen</em>) of Aarhus University, journal number 2016-051-000001, serial number 1339. Study II was approved by the Health in Central Denmark steering committee. The Health in Central Denmark project is registered in the Central Denmark Region internal register of research projects (reg. no. 1-16-02-165-20).</p>
<p>Access to register data was provided and approved by the Danish Health Data Authority and Statistics Denmark. In Denmark, studies based entirely on survey and register data do not require further ethical approval.</p>


<div id="refs" class="references csl-bib-body" role="doc-bibliography" style="display: none">
<div id="ref-reimbursement" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Danish Medicines Agency. <span class="nocase">Reimbursement thresholds</span> [Internet]. {2023; last accessed on 7 Feb 2023};Available from: <a href="https://laegemiddelstyrelsen.dk/en/reimbursement/calculate-reimbursement/reimbursement-thresholds/">https://laegemiddelstyrelsen.dk/en/reimbursement/calculate-reimbursement/reimbursement-thresholds/</a></div>
</div>
<div id="ref-okportal" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Danish Regions. <span class="nocase">OKPortal: Takstmapper [English: Contract agreement Portal: Rate folders]</span> [Internet]. {2023; last accessed on 7 Feb 2023};Available from: <a href="https://okportal.dk/Default.aspx?area=Praksis&amp;type=Takstmapper">https://okportal.dk/Default.aspx?area=Praksis&amp;type=Takstmapper</a></div>
</div>
<div id="ref-regsoverview" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Schmidt M, Schmidt SAJ, Adelborg K, et al. <a href="https://doi.org/10.2147/clep.S179083">The danish health care system and epidemiological research: From health care contacts to database records</a>. Clin Epidemiol 2019;11:563‚Äì91. </div>
</div>
<div id="ref-eurostat_equiv" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Eurostat. <span class="nocase">Glossary: Equivalised disposable income</span> [Internet]. {last accessed 7 Feb 2023};Available from: <a href="https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Glossary:Equivalised_disposable_income">https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Glossary:Equivalised_disposable_income</a></div>
</div>
<div id="ref-icd10" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">World Health Organisation. <span class="nocase">International statistical classification of diseases and related health problems, 10th revision: Instruction manual, fifth edition</span> [Internet]. {2016, last accessed 7 Feb 2023};Available from: <a href="https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2019.pdf">https://icd.who.int/browse10/Content/statichtml/ICD10Volume2_en_2019.pdf</a></div>
</div>
<div id="ref-rlrr" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Sundhedsdatastyrelsen [English: Danish Health Data Authority]. <span class="nocase">Dokumentation af Laboratoriedatabasens Forskertabel ‚Äì Version 1.3 [English: Documentation on Register of Laboratory Results for Research - version 1.3]</span> [Internet]. {2018, last accessed 7 Feb 2023};Available from: <a href="https://sundhedsdatastyrelsen.dk/-/media/sds/filer/registre-og-services/nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/laboratoriedatabasen/dokumentation-af-labdatabasens-forskertabel.pdf">https://sundhedsdatastyrelsen.dk/-/media/sds/filer/registre-og-services/nationale-sundhedsregistre/doedsaarsager-og-biologisk-materiale/laboratoriedatabasen/dokumentation-af-labdatabasens-forskertabel.pdf</a></div>
</div>
<div id="ref-ruks1doc" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Sundhedsdatastyrelsen [English: Danish Health Data Authority]. <span class="nocase">Algoritmer for udvalgte kroniske sygdomme og sv√¶re psykiske lidelser [English: Algorithms for selected chronic diseases and serious mental illnesses]</span> [Internet]. {2016, last accessed 7 Feb 2023};Available from: <a href="https://www.esundhed.dk/-/media/Files/Dokumentation/Register-for-Udvalgte-Kroniske-Sygdomme-og-Svaere-Psykiske-Lidelser/29_Algoritmer_for_RUKS.ashx">https://www.esundhed.dk/-/media/Files/Dokumentation/Register-for-Udvalgte-Kroniske-Sygdomme-og-Svaere-Psykiske-Lidelser/29_Algoritmer_for_RUKS.ashx</a></div>
</div>
<div id="ref-ddd" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Wertheimer AI. The defined daily dose system (DDD) for drug utilization review. Hosp Pharm 1986;21(3):233‚Äì4, 239‚Äì41, 258. </div>
</div>
<div id="ref-hicd" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Bjerg L, Dalsgaard E-M, Norman K, Isaksen AA, Sandb√¶k A. Cohort profile: Health in central denmark (HICD) cohort - a register-based questionnaire survey on diabetes and related complications in the central denmark region. BMJ Open [Internet] 2022;12(7):e060410. Available from: <a href="http://bmjopen.bmj.com/content/12/7/e060410.abstract">http://bmjopen.bmj.com/content/12/7/e060410.abstract</a></div>
</div>
<div id="ref-nhs" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Christensen AI, Ekholm O, Gl√ºmer C, et al. The danish national health survey 2010. Study design and respondent characteristics. Scandinavian Journal of Public Health [Internet] 2012;40(4):391‚Äì7. Available from: <a href="https://doi.org/10.1177/1403494812451412">https://doi.org/10.1177/1403494812451412</a></div>
</div>
<div id="ref-RStudio" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">RStudio Team. RStudio: Integrated development environment for r [Internet]. Boston, MA: RStudio, PBC; 2021. Available from: <a href="http://www.rstudio.com/">http://www.rstudio.com/</a></div>
</div>
<div id="ref-R" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: <a href="https://www.R-project.org/">https://www.R-project.org/</a></div>
</div>
<div id="ref-datatable" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Dowle M, Srinivasan A. Data.table: Extension of ‚Äòdata.frame‚Äò [Internet]. 2021. Available from: <a href="https://CRAN.R-project.org/package=data.table">https://CRAN.R-project.org/package=data.table</a></div>
</div>
<div id="ref-Epi" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Carstensen B, Plummer M, Laara E, Hills M. <span>Epi</span>: A package for statistical analysis in epidemiology [Internet]. 2021. Available from: <a href="https://CRAN.R-project.org/package=Epi">https://CRAN.R-project.org/package=Epi</a></div>
</div>
<div id="ref-finalfit" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">Harrison E, Drake T, Ots R. Finalfit: Quickly create elegant regression results tables and plots when modelling [Internet]. 2021. Available from: <a href="https://CRAN.R-project.org/package=finalfit">https://CRAN.R-project.org/package=finalfit</a></div>
</div>
<div id="ref-tidyverse" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Wickham H, Averick M, Bryan J, et al. <a href="https://doi.org/10.21105/joss.01686">Welcome to the <span class="nocase">tidyverse</span></a>. Journal of Open Source Software 2019;4(43):1686. </div>
</div>
<div id="ref-geepack" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Halekoh U, H√∏jsgaard S, Yan J. The r package geepack for generalized estimating equations. Journal of Statistical Software 2006;15/2:1‚Äì11. </div>
</div>
<div id="ref-diagrammer" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Iannone R. DiagrammeR: Graph/network visualization [Internet]. 2020. Available from: <a href="https://CRAN.R-project.org/package=DiagrammeR">https://CRAN.R-project.org/package=DiagrammeR</a></div>
</div>
<div id="ref-khroma" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Frerebeau N. Khroma: Colour schemes for scientific data visualization [Internet]. Pessac, France: Universit√© Bordeaux Montaigne; 2021. Available from: <a href="https://doi.org/10.5281/zenodo.1472077">https://doi.org/10.5281/zenodo.1472077</a></div>
</div>
<div id="ref-Grant2014" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Grant RL. <a href="https://doi.org/10.1136/bmj.f7450"><span class="nocase">Converting an odds ratio to a range of plausible relative risks for better communication of research findings</span></a>. BMJ 2014;348. </div>
</div>
<div id="ref-convergencefail" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Williamson T, Eliasziw M, Fick GH. Log-binomial models: Exploring failed convergence. Emerging Themes in Epidemiology [Internet] 2013;10(1):14. Available from: <a href="https://doi.org/10.1186/1742-7622-10-14">https://doi.org/10.1186/1742-7622-10-14</a></div>
</div>
<div id="ref-Zou2004" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Zou G. <a href="https://doi.org/10.1093/aje/kwh090"><span class="nocase">A Modified Poisson Regression Approach to Prospective Studies with Binary Data</span></a>. American Journal of Epidemiology 2004;159:702‚Äì6. </div>
</div>
<div id="ref-regresscounts" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Zeileis, Achim and Kleiber, Christian and Jackman, Simon. <span class="nocase">Regression Models for Count Data in R</span> [Internet]. {last accessed 7 Feb 2023};Available from: <a href="https://cran.r-project.org/web/packages/pscl/vignettes/countreg.pdf">https://cran.r-project.org/web/packages/pscl/vignettes/countreg.pdf</a></div>
</div>
<div id="ref-Greenland2004" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Greenland, Sander. <a href="https://doi.org/10.1093/aje/kwh221"><span class="nocase">Model-based Estimation of Relative Risks and Other Epidemiologic Measures in Studies of Common Outcomes and in Case-Control Studies</span></a>. American Journal of Epidemiology 2004;160(4):301‚Äì5. </div>
</div>
<div id="ref-compareperformance" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Chen W, Qian L, Shi J, Franklin M. Comparing performance between log-binomial and robust poisson regression models for estimating risk ratios under model misspecification. BMC Medical Research Methodology [Internet] 2018;18(1):63. Available from: <a href="https://doi.org/10.1186/s12874-018-0519-5">https://doi.org/10.1186/s12874-018-0519-5</a></div>
</div>
</div>
</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "Óßã";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
<nav class="page-navigation">
  <div class="nav-page nav-page-previous">
      <a href="./2-aims.html" class="pagination-link">
        <i class="bi bi-arrow-left-short"></i> <span class="nav-page-text"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></span>
      </a>          
  </div>
  <div class="nav-page nav-page-next">
      <a href="./4-results.html" class="pagination-link">
        <span class="nav-page-text"><span class="chapter-number">4</span>&nbsp; <span class="chapter-title">Results in summary</span></span> <i class="bi bi-arrow-right-short"></i>
      </a>
  </div>
</nav>
</div> <!-- /content -->



</body></html>